Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, descriptive observational study of Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa

Trial Profile

A prospective, descriptive observational study of Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Cefepime/tazobactam (Primary)
  • Indications Pseudomonal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2018 New trial record
    • 23 Aug 2018 Results published in the European Journal of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top